Screening for Eating Disorders in Psoriasis Patients: A Multicenter Cross-Sectional Study Authors: Laura Calabrese, Maria Letizia Musumeci, Romina Ortega, Federico Bardazzi, Lidia Sacchelli, Matteo Megna, Giuseppe Micali Published: 2026 ABSTRACT BackgroundPsoriasis is widely recognized as a systemic inflammatory condition associated with numerous comorbidities. Among these, eating disorders (ED) and ED-related behavior, defined as restrictive or dysfunctional attitudes toward food, have been increasingly reported in patients with psoriasis. Aim of our study was to evaluate the prevalence of ED-related symptoms in psoriasis patients with excess body weight and to explore their association with body mass index (BMI) across the overweight and obese ranges.MethodsA multicenter, cross-sectional study was conducted on adult patients with psoriasis and BMI ≥25 kg/m2. ED-related symptoms were assessed using the Binge Eating Scale (BES ≥17) and Eating Attitudes Test-26 (EAT-26). Screening positivity required a positive result in at least one questionnaire. Patients were stratified into four BMI categories. Variables were compared using standard non-parametric tests, and logistic regression assessed predictors of screening positivity.ResultsA total of 104 patients were included. Overall, 13 patients (12.5%) tested positive in at least one questionnaire. No statistically significant differences in the proportion of screening-positive patients were observed across the BMI categories or between the overweight and obese groups. Similarly, the mean BES and EAT-26 scores did not differ significantly between groups. Logistic regression analysis confirmed that BMI was not a significant predictor of ED-related screening positivity (OR = 0.942, 95% CI: 0.813–1.091). Spearman’s analysis showed no significant correlation between BMI and BES scores (ρ = 0.031, p = 0.753) but a weak negative correlation between BMI and EAT-26 scores (ρ = −0.211, p = 0.032).ConclusionApproximately one in eight psoriasis patients with excess body weight screened positive for ED-related symptoms. BMI category was not a predictor of ED-screening positivity. The weak negative correlation between BMI and restrictive eating attitudes indicates that dysfunctional eating behaviors may be more pronounced in patients with milder excess weight. Introduction Psoriasis is a chronic systemic inflammatory condition associated with numerous metabolic (obesity, metabolic syndrome, diabetes mellitus), cardiovascular, autoimmune, and psychiatric comorbidities.1–3 Patients with psoriasis show a higher prevalence of overweight, obesity, and metabolic syndrome compared to the general population, and increased body weight is associated with greater disease severity, systemic inflammation, and reduced therapeutic response.4,5 Obesity is considered a risk factor for the development and progression of psoriasis, which indicates a bidirectional relationship between these two conditions.6 Psoriasis is also associated with significant psychological burden, including depression, anxiety, social stigma, reduced self-esteem, and reduced quality of life, with psychiatric comorbidities generally very common in psoriasis.7,8 This psychological vulnerability is also associated with an increased susceptibility to eating disorders (EDs).9 The association between psoriasis and EDs is likely multifactorial, including maladaptive coping behaviors and shared inflammatory pathways that may exacerbate metabolic dysfunction and negatively impact the course of the disease.10 Disordered eating behaviors and restrictive or dysfunctional attitudes toward food are more commonly reported.9 Validated self-report instruments, such as the Binge Eating Scale (BES) and Eating Attitudes Test-26 (EAT-26), are widely used to screen for ED-related symptoms in clinical settings, identifying individuals at risk rather than establishing a formal clinical diagnosis.11,12 Despite growing interest, the available evidence on EDs and ED-related symptoms in psoriasis remains limited and heterogeneous, with inconsistent findings regarding their prevalence and relationship with body weight.10 Little is known about how ED-related symptoms are distributed across different body mass index (BMI) categories in patients with psoriasis. The aim of this study was to investigate the prevalence of positive screening results for ED-related symptoms in a multicenter Italian cohort of patients with psoriasis and BMI ≥25 kg/m2 and to assess whether their distribution differs across BMI classes within the overweight and obese range, thus assessing the potential association between BMI and the likelihood of ED-related symptoms. Subjects and Methods Study Population This multicenter, cross-sectional, observational study was conducted between June 2024 and September 2024 at three Italian dermatology centers (Policlinico of Catania, Policlinico of Bologna, and AOU Federico II of Naples). The study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the local ethic committee “Comitato Etico Locale Catania 1” (Protocol number: DIICA-37749). Written informed consent was obtained from all participants prior to enrollment. Consecutive adult patients (aged 18–75 years) with a clinical diagnosis of psoriasis, irrespective of disease severity or ongoing treatment, were prospectively enrolled. Eligible patients were required to have BMI ≥25 kg/m2. Exclusion criteria included a previously established diagnosis of ED, current or recent use of medications known to significantly affect body weight, severe psychiatric comorbidities precluding questionnaire completion, and inability to provide informed consent. BMI was calculated as the weight in kilograms divided by the height in meters squared (kg/m2). According to World Health Organization (WHO) criteria, patients were stratified into the following BMI categories: overweight (25–29.9 kg/m2), obesity class I (30–34.9 kg/m2), obesity class II (35–39.9 kg/m2), and obesity class III (≥40.0 kg/m2). ED-related symptoms were evaluated using two validated self-administered questionnaires, BES11 and EAT-26.12 The BES was used to assess uncontrolled and binge-related eating behaviors; a score ≥17 was considered indicative of clinically relevant ED-related symptoms. The EAT-26 was used to evaluate restrictive and dysfunctional eating attitudes; a score ≥20 was considered indicative of an increased risk of ED-related symptoms. Patients scoring above the established cut-off on at least one instrument were classified as positive. Statistical Analyses Categorical variables are expressed as absolute numbers and percentages. The proportion of screening-positive patients was described across the four BMI categories. Differences in the distribution of screening-positive and screening-negative patients across BMI categories were assessed using Fisher’s exact test, given the small cell count. Additionally, patients were grouped into two broader BMI categories [overweight (25–29.9 kg/m2) vs obese (≥30 kg/m2)], and the distribution of screening positivity between these groups was compared using the chi-square test. The mean BES and EAT-26 scores were compared between the overweight and obese groups using the nonparametric Mann–Whitney U-test. Additionally, logistic regression was performed to evaluate BMI as a predictor of ED-related screening positivity, expressed as odds ratios (OR) with 95% confidence intervals (CI). To further explore the relationship between BMI as a continuous variable and ED-related symptoms, the Spearman’s rank correlation coefficient (ρ) was calculated for the BMI-BES and BMI-EAT-26 pairs, given the non-normal distribution of the variables. Statistical significance was set at P <0.05. All statistical analyses were performed using GraphPad Prism (version 10.6.1, GraphPad Software, San Diego, CA, USA). Results A total of 104 patients were included in the study, with a mean age of 49.7 ± 12.5 years. 62 were male and 42 were female. In terms of BMI distribution, 42 patients (40.4%) were classified as overweight, 33 (31.7%) as obesity class I, 22 (21.2%) as obesity class II, and seven (6.7%) as obesity class III. Overall, 13 patients (12.5%) screened positive for ED-related symptoms on at least one questionnaire, including 9 women and 4 men. Of these, five (4.8%) were positive on the BES only, six (5.8%) on the EAT-26 only, and two (1.9%) on both instruments. The proportion of patients positive to ED-related symptoms screening across the four BMI categories was 16.7% (7/42) in the 25–29.9 kg/m2 group, 9.1% (3/33) in the 30–34.9 kg/m2 group, 9.1% (2/22), 35–39.9 kg/m2 group, and 14.3% (1/7) in the ≥40 kg/m2 group (Figure 1). No statistically significant difference was observed across the BMI categories (Fisher’s exact test, p = 0.75) (Table 1).Table 1Comparison of ED-Related Screening Positivity Across Different BMI CategoriesBMI Category (kg/m2)ED-Screening Positive n (%)ED-Screening Negative n (%)TotalFisher’s Exact Test25-29.97 (16.7%)35 (83.3%)4230-34.93 (9.1%)30 (90.9%)3335-39.92 (9.1%)20 (90.9%)22≥401 (14.3%)6 (85.7%)7Overall13 (12.5%)91 (87.5%)104p: 0.75Abbreviations: BMI, body mass index; ED, eating disorders. Figure 1Distribution of EDs screening positivity across BMI categories. The proportion of patients screening positive for eating disorder–related symptoms is reported for each BMI group (25–29.9, 30–34.9, 35–39.9, and ≥40 kg/m2). Percentages are calculated within each BMI category. ED-positive patients were defined as those scoring above the established cut-off on at least one of the administered questionnaires (BES or EAT-26).A bar graph showing eating disorder screening positivity across body mass index categories in psoriasis patients. Table 1Comparison of ED-Related Screening Positivity Across Different BMI CategoriesBMI Category (kg/m2)ED-Screening Positive n (%)ED-Screening Negative n (%)TotalFisher’s Exact Test25-29.97 (16.7%)35 (83.3%)4230-34.93 (9.1%)30 (90.9%)3335-39.92 (9.1%)20 (90.9%)22≥401 (14.3%)6 (85.7%)7Overall13 (12.5%)91 (87.5%)104p: 0.75Abbreviations: BMI, body mass index; ED, eating disorders. Comparison of ED-Related Screening Positivity Across Different BMI Categories Abbreviations: BMI, body mass index; ED, eating disorders. Distribution of EDs screening positivity across BMI categories. The proportion of patients screening positive for eating disorder–related symptoms is reported for each BMI group (25–29.9, 30–34.9, 35–39.9, and ≥40 kg/m2). Percentages are calculated within each BMI category. ED-positive patients were defined as those scoring above the established cut-off on at least one of the administered questionnaires (BES or EAT-26). When the patients were dichotomized into overweight and obese groups, the proportion of ED-positive patients was 16.7% (7/42) and 9.7% (6/62), respectively, with no significant difference between the two groups (χ2-test, p = 0.3) (Table 2).Table 2Comparison of ED-Related Screening Positivity Between Overweight and Obese PatientsBMI GroupED-Screening Positive n (%)ED-Screening Negative n (%)TotalChi Squared Test25–29.9 kg/m27 (16.7%)35 (83.3%)42≥30 kg/m26 (9.7%)56 (90.3%)62Total13 (12.5%)91 (87.5%)104χ2: 1.118, p: 0.3Abbreviations: BMI, body mass index; ED, eating disorders. Table 2Comparison of ED-Related Screening Positivity Between Overweight and Obese PatientsBMI GroupED-Screening Positive n (%)ED-Screening Negative n (%)TotalChi Squared Test25–29.9 kg/m27 (16.7%)35 (83.3%)42≥30 kg/m26 (9.7%)56 (90.3%)62Total13 (12.5%)91 (87.5%)104χ2: 1.118, p: 0.3Abbreviations: BMI, body mass index; ED, eating disorders. Comparison of ED-Related Screening Positivity Between Overweight and Obese Patients Abbreviations: BMI, body mass index; ED, eating disorders. To further investigate the relationship between BMI and ED-related symptom burden beyond categorical analysis, continuous scores were compared across groups. No statistically significant difference in BES scores was observed between overweight and obese patients (3.5 [IQR 2.0–9.8] vs 5.5 [IQR 2.0–12.0]; p = 0.549), and EAT-26 scores were similar between groups (7.0 [IQR 4.0–11.8] vs 4.5 [IQR 2.0–9.8]; p = 0.106) (Table 3). Furthermore, logistic regression analysis confirmed that BMI was not a significant predictor of ED-related screening positivity (OR = 0.942 per unit BMI increase, 95% CI: 0.813–1.091, p = 0.424) (Table 4). Finally, we explored the relationship between BMI and ED-related symptoms, and Spearman correlation analysis revealed no significant association between BMI and BES scores (ρ = 0.031, p = 0.753), whereas a weak but statistically significant negative correlation was observed between BMI and EAT-26 scores (ρ = −0.211, p = 0.032), suggesting that restrictive eating attitudes may be more pronounced in patients with lower BMI values within the excess weight range (Table 5).Table 3Mann–Whitney U-Test Comparison of BES and EAT-26 Scores Between Overweight and Obese Patients with PsoriasisVariableOverweightN=42(median [IQR])ObeseN=62(median [IQR])Up-valueBES3.5 [2.0–9.8]5.5 [2.0–12.0]1211.50.54EAT-267.0 [4.0–11.8]4.5 [2.0–9.8]15460.106Abbreviations: IQR, Interquartile range; BES, binge eating scale; EAT-26, eating attitude test-26. Table 4Logistic Regression: BMI and ED-Related Screening Positivity in Psoriasis PatientVariableOR95% CIp-valueBMI (per 1 kg/m2 increase)0.9420.813–1.0910.424Abbreviations: BMI, Body mass index; OR, Odds Ratio; CI, confidence interval; EDs, Eating Disorders. Table 5Spearman’s Rank Correlation Between BMI and ED Screening ScoresVariable PairNumber of Patientsρ95% CIp-valueBMI vs BES1040.031[−0.163; 0.222]0.753BMI vs EAT-26104−0.211[−0.388; −0.019]0.032Note: Bold values indicate statistical significance (p < 0.05).Abbreviations: BMI, body mass index; BES, binge eating scale; EAT-26, eating attitude test-26; CI, confidence interval; ED, eating disorder. Table 3Mann–Whitney U-Test Comparison of BES and EAT-26 Scores Between Overweight and Obese Patients with PsoriasisVariableOverweightN=42(median [IQR])ObeseN=62(median [IQR])Up-valueBES3.5 [2.0–9.8]5.5 [2.0–12.0]1211.50.54EAT-267.0 [4.0–11.8]4.5 [2.0–9.8]15460.106Abbreviations: IQR, Interquartile range; BES, binge eating scale; EAT-26, eating attitude test-26. Mann–Whitney U-Test Comparison of BES and EAT-26 Scores Between Overweight and Obese Patients with Psoriasis Abbreviations: IQR, Interquartile range; BES, binge eating scale; EAT-26, eating attitude test-26. Table 4Logistic Regression: BMI and ED-Related Screening Positivity in Psoriasis PatientVariableOR95% CIp-valueBMI (per 1 kg/m2 increase)0.9420.813–1.0910.424Abbreviations: BMI, Body mass index; OR, Odds Ratio; CI, confidence interval; EDs, Eating Disorders. Logistic Regression: BMI and ED-Related Screening Positivity in Psoriasis Patient Abbreviations: BMI, Body mass index; OR, Odds Ratio; CI, confidence interval; EDs, Eating Disorders. Table 5Spearman’s Rank Correlation Between BMI and ED Screening ScoresVariable PairNumber of Patientsρ95% CIp-valueBMI vs BES1040.031[−0.163; 0.222]0.753BMI vs EAT-26104−0.211[−0.388; −0.019]0.032Note: Bold values indicate statistical significance (p < 0.05).Abbreviations: BMI, body mass index; BES, binge eating scale; EAT-26, eating attitude test-26; CI, confidence interval; ED, eating disorder. Spearman’s Rank Correlation Between BMI and ED Screening Scores Note: Bold values indicate statistical significance (p < 0.05). Abbreviations: BMI, body mass index; BES, binge eating scale; EAT-26, eating attitude test-26; CI, confidence interval; ED, eating disorder. Discussion In our cohort, 12.5% of psoriasis patients were positive on at least one ED risk assessment tool, with limited overlap between BES and EAT-26 positivity (only two patients scored above the cutoff on both). This pattern supports the existence of differentiated behavioral profiles in psoriasis; some patients predominantly express a loss of control over eating, while others display a restrictive or dysfunctional attitude towards food and body weight, reflecting different and not necessarily overlapping psychopathological dimensions. The marked female predominance among patients with ED-related symptoms (9 of 13) is consistent with previous evidence indicating a greater susceptibility to ED among women with psoriasis,10,13 as well as in different clinical populations.14 Contrary to the intuitive expectation that a greater degree of obesity would be associated with more eating disorders, no significant association emerged between BMI categories and ED screening positivity in our cohort. The distribution of patients with ED-related symptoms across the four BMI classes was statistically comparable, and no significant difference was observed when patients were dichotomized into overweight and obese groups. These findings were further confirmed by additional analyses: BES and EAT-26 scores did not differ significantly between overweight and obese patients, and logistic regression confirmed the absence of a significant association between BMI and the likelihood of a positive ED-related screening test. Taken together, these results suggest that BMI alone may not be a reliable predictor of ED-related psychopathology in overweight psoriasis patients and that psychological and behavioral vulnerabilities may be evenly distributed across weight categories rather than concentrated in the most obese subgroups. An interesting finding of this study came from Spearman correlation analysis, which revealed a weak but statistically significant negative association between BMI and EAT-26 scores (ρ = −0.211, p = 0.032), while no such association was observed for BES scores (ρ = 0.031, p = 0.753). Thus, restrictive and dysfunctional eating attitudes, as reflected in the EAT-26, appear to correlate with lower BMI values within the overweight range, whereas binge eating behaviors are more evenly distributed, regardless of the degree of obesity. One possible interpretation is that overweight patients, closer to the normal weight threshold, may be more prone to actively abstain from eating due to body image concerns or social pressure to lose weight. In psoriasis, where visible skin involvement further exacerbates body image disturbances and social stigma, this dynamic may be particularly relevant.15 These findings suggest that screening for erectile dysfunction (ED) in psoriasis should not be reserved for patients with high BMI, as restrictive eating attitudes may be particularly prevalent in those with milder degrees of overweight. Compared with the existing literature, our prevalence rate of ED screening positivity in psoriasis (12.5%) was partially consistent with previous reports. Brănișteanu et al16 identified binge eating behaviors in 7.9% of a cohort of 316 psoriasis patients, assessed by the BES (score ≥18). Altunay et al10 found that 7% of 100 psoriasis patients scored at or above the clinical threshold on the EAT-40 (score ≥30), indicating a high risk of eating disorders. None of these studies reported data stratified by BMI, limiting their ability to assess the contribution of overweight to the observed findings. Temel et al17 in a cohort of 82 psoriasis patients, found that 12.2% of the total sample tested positive for the EAT-26 (score ≥20). When stratified by BMI, overweight and obese patients showed significantly higher EAT-26 scores than normal weight patients. On a broader epidemiological level, Hedman et al13 identified a bidirectional relationship between EDs and autoimmune diseases, including psoriasis, which was particularly pronounced in women; this pattern was also reflected in our cohort. Crosta et al9 documented a significant association between increased BMI and worsening Eating Disorders Inventory (EDI) scores in patients with psoriasis, with higher BMI correlating with greater body dissatisfaction and bulimia-related symptoms. This is in part in contrast to our results, which did not show a progressive increase in ED screening positivity with increasing BMI class. This difference may reflect methodological differences, including the use of different instruments (EDI vs BES and EAT-26), and requires further investigation in larger cohorts. This study has several limitations that should be considered when interpreting the findings. This cross-sectional design precludes any causal inferences between body mass index (BMI) and symptoms related to erectile dysfunction (ED). Overall, the sample size was limited, particularly in the highest BMI category, which may have reduced the statistical power of subgroup comparisons. No information was collected on disease severity and duration or current systemic or biologic treatments, all of which may independently affect both body weight and psychological outcomes. In addition, the use of validated screening instruments rather than structured psychiatric diagnostic interviews means that the reported rates reflect screening positivity rather than confirmed clinical diagnoses in the ED. Finally, the absence of a non-psoriasis control group with a comparable BMI distribution limited the ability to specifically attribute the observed prevalence to psoriasis. Conclusion In this study, approximately one in eight overweight psoriasis patients tested positive for ED-related symptoms, with no significant association between BMI class and screening positivity. The weak but significant negative correlation between BMI and EAT-26 scores suggests that restrictive eating attitudes may be more common in patients with lower BMIs within the overweight range. Taken together, these findings suggest that BMI alone should not guide patient selection for ED screening in patients with psoriasis and that a comprehensive approach that includes both binge eating and restrictive eating attitudes is useful in clinical practice. Further prospective studies with larger cohorts and control groups are needed to confirm and extend these findings.